SBIR/STTR Research Award

Developing blood-based exercise mimetic as a treatment for Alzheimer's disease and related dementias

Award identifier 10a2c87b75a162818a5150b23df5e24f04810e25a768c55835a7af48677df44dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$509,038

Program and phase

STTR · Phase I

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Ceiba Bio Inc.
Proposal award date
2024-09-01
Contract end date
2025-08-31
UEI
TPSUW64H9M35
Solicitation number
PAS22-197
Topic code
R

Research abstract

Project Summary Despite the growing number of adults that are living with Alzheimer’s disease (AD) worldwide, there still lacks disease modifying treatments. Physical activity and exercise mitigate AD risk and boosts cognitive functions in patients, yet over a quarter of the elderly do not meet these activity guidelines, often due to physical limitations and resource constraints. Current therapeutic approaches focused on AD are restricted to targeting neuropathology within the central nervous system. Thus, there is an imperative need to develop alternative therapies that confer benefits of exercise to AD patients, circumventing their physical limitations. Prior work by our research team identified Glycosylphosphatidylinositol-Specific Phospholipase D1 (Gpld1) an exercise-induced circulating factor in blood plasma that mediates the neurogenic and cognitive benefits of exercise in aged mice and shows neurobehavioral relevance in elderly human adults. Systemically increasing Gpld1 levels in blood mimicked the beneficial effects of exercise on cognitive function and AD-related neuropathology in aged mice and mouse models of AD pathology. The purpose of this study is to translate the scientific discoveries identifying peripheral targets in blood – GPLD1 in particular – as novel potential therapeutic blood-based exercise mimetics to treat AD- related dementias. We will achieve this with Three Specific Aims: 1: Identify three lead recombinant human GPLD1 molecules. 2: Establish optimal exposure through extensive in vivo PK profiling in aged wild type mice of the three lead recombinant human GPLD1 molecules. 3: Test one primary and one alternate lead recombinant human GPLD1 molecule for disease modification in the 5xFAD mouse model of AD pathology. Successful completion of these aims is the critical first step for the identification and commercialization of potential therapeutic blood- based exercise mimetics to treat AD-related dementias.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2024–2025). Reported award amounts total $1,015,236. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.